KAYLEIGH GEISER: Open Payments
NPI 1104492867 · BROOKVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$536 in 40 payments from 8 companies in 2025. Trend: 2023 $234 · 2024 $528 · 2025 $536
Food & beverage: $536
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $200 |
| Novo Nordisk Inc | 13 | $156 |
| Lilly USA, LLC | 5 | $76 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen Inc. | 1 | $14 |
| Corium, LLC | 1 | $11 |
Products named: VRAYLAR, Ozempic, MOUNJARO, Rybelsus, QULIPTA, REXULTI, BREZTRI, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
